NCT06304805Befejeződött1. fázis
TGRX-326 Pharmacokinetic Food Effect Bioavailability Study
A Randomized, Open-label, Single-dose, 3-cycle, 6-sequence, Crossover Study Evaluating Food Effect on Pharmacokinetic Profiles of TGRX-326 in Chinese Healthy Subjects and Effect of Drug Specification on Bioavailability in Human
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. máj. 18.
Rövid összefoglaló (regiszter, angolul)
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-326 and the effect of different drug specifications on human bioavailability for TGRX-326, a drug indicated for non-small cell lung cancer treatment
- Állapot (regiszter)
- Befejeződött
- Fázis (regiszter)
- 1. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 24 (tényleges)
- Első benyújtás
- 2024. márc. 5.
- Kezdés
- 2023. dec. 13.
- Elsődleges befejezés
- 2024. jan. 12.
- Fő szponzor
- Shenzhen TargetRx Co., Ltd.
- Betegségek
- Tüdőrák
- NCT-szám
- NCT06304805
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 1. fázis
- Bevont résztvevők: 24
- 2023. dec. 13. és az elsődleges befejezés (2024. jan. 12.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- history of major surgery within 3 months before first dose, or have plans to receive surgery during the study, or history of any surgery that could affect drug absorption, distribution, metabolism and excretion
- use of any investigational drug or participation of any clinical study (for drug or medical device) within 3 months before first dose, or cannot participate the study in person/on site
- history of blood donation, blood loss (>= 400 mL, excluding normal blood loss during female menstrual period), or reception of blood transfusion within 3 months before screening
- history of daily cigarette consumption of more than 5 within 3 months before screening, or cannot avoid using cigarette/tabacco products during the study
- history of alcohol abuse (more than 14 units of alcohol per week) within 3 months before screening, or cannot avoid alcohol consumption during study
- history of large tea/coffee/caffeinated drink intake (more than 8 cups per day) within 3 months before first dose
- use of any prescription / over-the-counter drug, or Chinese herbal medication, or health supplementary products within 14 days of test article administration
- vaccination within 14 days before first test article administration, or have plans to receive vaccination during the study period
- history of unprotected sexual activities within 14 days before first dose
- consumption of food or drink rich in caffeine/xanthine (such as chocolate, coffee, tea, coke) or food/food product of grapefruit, dragon fruit, mango, tangerine, or any food that could affect drug absorption, distribution, metabolism and excretion
Más betegség
- history of allergic reactions, or allergic to any components to the study drugs that by investigator's judgement unsuitable for the study
- any clinically significant conditions that could affect study outcomes, safety or compliance
- have difficulties to receive venous needle puncture, or cannot tolerate venous needle puncture, or history of hematophobia or needle sickness
- history of substance abuse
- any one positive result for hepatitis-B surface antigen, Hepatitis C antibody, HIV antibody or syphilis antibody
Laborértékek
- history of irregular dietary schedule within 1 months of first dose (including, dieting, overeating, low sodium intake, etc.)
Egyéb
- have special food requirement or cannot follow food requirement of the study, or lactose intolerant
- alcohol breathing test results of > 0.0 mg/100mL for blood alcohol concentration
- positive test results on substance use (including, morphine, methylamphetamine, ketamine, tetrahydrocannabinol, methylene-dioxy-methyl-amphetamine)
- female in pregnancy or breastfeeding period, or positive pregnancy test result
- any reasons that is deemed unsuitable for study participation as determined by investigator
Kiket keres a vizsgálat
- able to understand the purpose, methods and possible adverse events of the study and agree to volunteering consent before the start of study
- healthy subject; male or female
- Age between 18 and 55 (inclusive)
- body mass index (BMI) between 19.0 and 26.0 (inclusive), male weight <=50 kg, female weight <=45 kg
- normal/ clinically insignificant test results (including physical exam, laboratory tests, 12-lead ECG, chest x-ray, etc.)
- participant/partner of the participant does not have plans for child bearing from screening until 6 months after study, and is willing to take contraceptive measures during study period and for 6 months, and does not have plans to donate sperm/egg during the said period
Életkor a regiszterben: 18 év – 55 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| First Affiliated Hospital Bengbu Medical College | Bengbu | Kína | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.